The designation of a patient’s tumor for individual HRR status assessment is important because therapeutic efficacy or patient prognosis vary according to the identification of genetic variations (e.g. BRCA1/2; RAD51, CDK12), the nature of these variations (i.e. pathogenic germline variant, somatic mutation, epigenetic change), and the site of these mutations (e.g. c.179 to c.505, c. Here, BRCA1 is linked to neoplasm.